Refine by
Bio Pharma Articles & Analysis: Older
41 news found
Watertown, MA — November 25, 2024—In the spirit of Thanksgiving, Biopharma PEG Scientific Inc. would like to express its sincere gratitude to our esteemed customers and partners for their trust and support. It is a privilege to collaborate with you, and we look forward to further strengthening our partnership in the future.As a gesture of our appreciation, we are pleased to announce a 30% ...
” At Huateng Pharma, we specialize in providing a diverse range of PEGs, available from grams to 100 kilograms, all produced under strict GMP standards. ...
W3P16.Attendees of CPHI China 2024 are invited to visit Huateng Pharma’s booth to explore the company’s latest advancements in PEG technology and CDMO capabilities. The company is renowned for providing comprehensive support to the bio-pharmaceutical industry, leveraging its expertise in PEG derivatives to enhance drug delivery systems and therapeutic ...
The four new members join OpenFold’s founders: Mohammed AlQuraishi’s Laboratory, Cyrus Biotechnology, Arzeda, Outpace Bio and Genentech’s Prescient Design. Bayer of Leverkusen, Germany, is a global enterprise with core competencies in the life science fields of health care and nutrition. ...
Carlo Incerti, Chairman of the Board of Inversago Pharma, commented: “We warmly welcome Ed and Nanna on their timely appointment to our board of directors and look forward to working together with them as the Company prepares for an imminent Phase 2 trial with its lead molecule INV-202. ...
The selected companies from seven European countries are A4Cell, AbolerIS Pharma, Abscint, ANeuroTech, Aptus, Bloomlife, Clouds of Care, E-scopics, FluoSphera, Iomed, Lattice Medical, mimiX biotherapeutics, Neomatrix, Neuropath, Predilife, Pulsify Medical, Radiomics, Regen Lab, Smart immune, Transactiva, Vidac Pharma Ltd., Leucid Bio, ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. ...
The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the 'China Pharmaceutical Bio Investment Briefing (IR)' on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. ...
Guy Chamberland, Chief Executive Officer and Chief Regulatory Officer of Tetra Bio-Pharma. About PPP004 PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. ...
Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. Details are as follows: MAY 16-18, 2022 François Ravenelle and Glenn Crater will be available for 1-on-1 meetings with the investment community during Bio€quity Europe. ...
Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. ...
OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that Health Canada approved the amendment of a phase I study conducted in collaboration with Dr. ...
OTTAWA, ON, Feb. 14, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced today that it has executed a non-binding term sheet with Avicanna Inc. ...
Under the license agreement, Grand Pharma is entitled to develop, manufacture and commercialize the Saturn device in Mainland China, Hong Kong, Macau and Taiwan. ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. GLK-302 is the second investigational ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). ...
SAN CLEMENTE, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today that it is presenting at the H.C. Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. Morgan 40th Annual Healthcare Conference. Details of the events and presentation are as ...
OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for ...
Topic: Makya: AI-driven de novo drug design and multi-parametric optimisation Recording Duration: 56:50 Webinar Start Time: Dec 7, 2021, 10 - 11 AM CET & 5 - 6 PM CET Access to the Recorded ...
ByIktos